Form 8-K - Current report:
SEC Accession No. 0001193125-25-117245
Filing Date
2025-05-12
Accepted
2025-05-12 06:25:46
Documents
14
Period of Report
2025-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d23036d8k.htm   iXBRL 8-K 35524
2 EX-99.1 d23036dex991.htm EX-99.1 75778
  Complete submission text file 0001193125-25-117245.txt   247375

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20250512.xsd EX-101.SCH 2835
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20250512_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20250512_pre.xml EX-101.PRE 11251
16 EXTRACTED XBRL INSTANCE DOCUMENT d23036d8k_htm.xml XML 3655
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 25932489
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)